Metycor

Metyrapone, the active ingredient in Metycor, is a 11β-hydroxylase inhibitor presented as a tablet for oral use. It is used in diagnostic testing of adrenal insufficiency and in the treatment of Cushing's syndrome in adults.

GNH USA supplies Metycor as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metyrapone acts on adrenal cortisol synthesis and is employed in specific endocrine indications.

- Diagnostic testing of adrenal insufficiency: helps assess adrenal reserve by blocking cortisol production for stimulation testing. - Treatment of Cushing's syndrome: reduces excess cortisol synthesis to control hypercortisolism. - Evaluation of ACTH-dependent disorders: assists in differentiating pituitary from ectopic ACTH sources during endocrine work‑up.

Metyrapone may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea - Dizziness - Fatigue - Abdominal discomfort

Serious or Rare Side Effects: - Adrenal crisis due to abrupt cortisol depletion - Severe hypotension - Hyponatremia or electrolyte imbalance - Allergic reactions such as rash or angioedema - Hepatic dysfunction

When using Metyrapone, clinicians should consider several safety measures.

- Monitor cortisol levels: regular testing is needed to avoid adrenal insufficiency. - Assess adrenal function before discontinuation: tapering may be required. - Use caution in patients with cardiovascular disease: hypotensive effects can be pronounced. - Avoid in individuals with known hypersensitivity to metyrapone or excipients. - Adjust use in hepatic impairment: liver function should be evaluated. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Metyrapone can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Ketoconazole (strong CYP3A4 inhibitor): may increase metyrapone plasma concentrations. - Concurrent glucocorticoids: can mask signs of adrenal insufficiency. - Rifampin or other CYP3A4 inducers: may markedly reduce metyrapone effectiveness.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive hypotensive effect may occur. - Diuretics: can exacerbate electrolyte disturbances. - Oral contraceptives: hormonal balance may be altered, requiring monitoring.